21.5.2024 08:08:49 CEST | Demant A/S | Investor News

Investor News                                                          21 May 2024

Closing of the divestment of our cochlear implants business

 

 

Today, Demant announces that all regulatory approvals and customary closing conditions regarding the divestment of our cochlear implants business to Cochlear have been fulfilled and that the proposed transaction has closed effective 21 May 2024. This is in line with expectations, and in the transition period, we will work closely together with Cochlear to ensure a smooth and proper transition so they can continue to service the existing cochlear implants patients.

 

Following the closing of the divestment, we still expect profit after tax related to Hearing Implants to be around DKK 0 million for 2024. Our bone anchored hearing systems business (BAHS) remains with the Group for now, pending a review of strategic options.

 

 

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

René Schneider, CFO

Peter Pudselykke, Head of Investor Relations

Henrik Axel Lynge Buchter, Manager of External Communications

 

 

Contacts

  • Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.

Attachments

  • 240521 Closing of divestment of cochlear implants business.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases